Immunological effectiveness of the booster Soberana Plus vaccine (FINLAY-FR-1A)
https://doi.org/10.51523/2708-6011.2024-21-4-03
Abstract
Objective. To assess the efficacy of immunogenicity of the Soberana Plus (FINLAY-FR-1A) vaccine in adults previously vaccinated against COVID-19.
Materials and methods. A total of 98 participants participated in the study. The immunogenicity of the Soberana Plus (FINLAY-FR-1A) vaccine was studied by measuring IgG concentration to SARS-CoV-2 by enzyme-linked immunosorbent assay (ELISA) at 4 study sites: day 0, in 42 days, 90 days and 180 days after the Soberana Plus (FINLAY-FR-1A) administration.
Results. Participants of the study were divided into groups based on their primary immunization: 1) Sputnik V (Gam-COVID-Vac) / Sputnik Light; 2) Sinopharm (BBIBP-CorV); 3) Sinopharm (BBIBP-CorV) + Sputnik V (Gam-COVIDVac) / Sputnik Light. The highest IgG level was observed in 90 days after administration of booster dose (p< 0,001). At the “90 day” point, IgG levels were higher in the previously vaccinated with Sputnik V (Gam-COVID-Vac) / Sputnik Light + Sinopharm (BBIBP-CorV), however, this group had higher IgG levels before the Soberana Plus (FINLAY-FR-1A) administration. In 42 days after vaccination, participants of the age group “45 plus” had the highest IgG level, and in 180 days participants of the age group “45 plus” had the highest IgG level compared to the age group “25-45 years old” (р=0,048).
Conclusion. Soberana Plus (FINLAY-FR-1A) vaccine is quite immunogenic. The highest level of IgG to SARS-CoV-2 marked on day 90 (р
Supporting agencies: The study was conducted without sponsorship.
About the Authors
K. S. Korsak
Gomel State Medical University
Belarus
Belarus
Katsiaryna S. Korsak, Assistant Lecturer at the Department of Epidemiology and Evidence-based Medicine
Gomel
E. V. Voropaev
Gomel State Medical University
Belarus
Belarus
Evgenii V. Voropaev, Candidate of Medical Sciences, Associate Professor, Vice-rector for Scientific Work
Gomel
O. V. Osipkina
Gomel State Medical University
Belarus
Belarus
Olga V. Osipkina, Head of the Research Laboratory
Gomel
A. A. Kovalev
Gomel State Medical University
Belarus
Belarus
Alexey A. Kovalev, Senior Lecturer at the Department of Medical and Biological Physics, Software Engineer at the Center for Science, Medical Information and Clinical Trials
Gomel
I. O. Stoma
Gomel State Medical University
Belarus
Belarus
Igor O. Stoma, Doctor of Medical Sciences, Professor, Rector
Gomel
References
1. Kuriyama K, Murakami K, Masuda T, Sugiura K, Sakui S, Schuring RP, et al. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial. Vaccine. 2023;41(25):3763-3771. DOI: https://doi.org/10.1016/j.vaccine.2023.05.001
2. Raiser F, Davis M, Adelglass J, Cai MR, Chau G, CloneyClark S, et al. Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults. Vaccine. 2023;41(41):5965-5973. DOI: https://doi.org/10.1016/j.vaccine.2023.07.056
3. Jaggaiahgari S, Munigela A, Mitnala S, Gujjarlapudi D, Simhadri V, D NR. Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2. Vaccines (Basel). 2022;10(12):2146. DOI: https://doi.org/10.3390/vaccines10122146
4. Qassim SH, Chemaitelly H, Ayoub HH, Coyle P, Tang P, Yassine HM, et al. Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study. eClinicalMedicine. 2023;62:102102. DOI: https://doi.org/10.1016/j.eclinm.2023.102102
5. Tabarsi P, Anjidani N, Shahpari R, Roshanzamir K, Fallah N, Andre G, et al. Immunogenicity and safety of SpikoGen®, an adjuvanted recombinant SARS-CoV2 spike protein vaccine as a homologous and heterologous booster vaccination: A randomized placebocontrolled trial. Immunology. 2022;167(3):340-353. DOI: https://doi.org/10.1111/imm.13540
6. Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, et al. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial. Signal Transduction Targeted Therapy. 2022;7:172. DOI: https://doi.org/10.1111/imm.13540
7. Wang XY, Mahmood SF, Jin F, Cheah WK, Ahmad M, Sohail MA, et al. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebocontrolled phase III trial. Emerging Microbes & Infections. 2022;11(1):1910-1919. DOI: https://doi.org/10.1080/22221751.2022.2088406
8. Mallory RM, Formica N, Pfeiffer S, Wilkinson B, Marcheschi A, Albert G, et al. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial. The Lancet Infectious Diseases. 2022;22(11):1565-1576. DOI: https://doi.org/10.1016/S1473-3099(22)00420-0
9. Estephan L, Lin YC, Lin YT, Chen YH, Pan SC, Hsieh SM, et al. Safety and immunogenicity of homologous versus heterologous booster dose with AZD1222, mRNA-1273, or MVC-COV1901 SARS-CoV-2 vaccines in adults: An observerblinded, multi-center, phase 2 randomized trial. Vaccine. 2023;41(23):3497-3505. DOI: https://doi.org/10.1016/j.vaccine.2023.04.029
10. Marchese AM, Kalkeri R, Vadivale M, Suntronwong N, Toback S, Poovorawan Y. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines. Expert Review of Vaccines. 2023;22(1):620-628. DOI: https://doi.org/10.1080/14760584.2023.2232020
11. Wickham H, Averick M, Bryan J, Chang W, McGowan LD, François R, et al. Welcome to the tidyverse. Journal of Open Source Software. 2019;4(43):1686. DOI: https://doi.org/10.21105/joss.01686
12. Kassambara A. rstatix: Pipe-Friendly Framework for Basic Statistical Tests. R package version 0.7.1. Published: 2023.02.01. [date of access 2024 august 18]. Available from: https://CRAN.R-project.org/package=rstatix
13. Pohlert T. PMCMRplus: Calculate Pairwise Multiple Comparisons of Mean Rank Sums Extended. R package version 1.9.4. [date of access 2024 august 18]. Available from: https://CRAN.R-project.org/package=PMCMRplus
14. Patil I. Visualizations with statistical details: The ‘ggstatsplot’ approach. Journal of Open Source Software. 2021;6(61):3167. DOI: https://doi.org/10.21105/joss.03167
15. Kassambara A. ggpubr: ‘ggplot2’ Based Publication Ready Plots. R package version 0.4.0. (2020). [date of access 2024 august 18]. Available from: https://CRAN.R-project.org/package=ggpubr
16. Toledo-Romaní ME, García-Carmenate M, ValenzuelaSilva C, Baldoquín-Rodríguez W, Martínez-Pérez M, RodríguezGonzález M, et al. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinicaltrial. The Lancet Regional Health – Americas. 2022;18:100423. DOI: https://doi.org/10.1016/j.lana.2022.100423
17. Mostafavi E, Eybpoosh S, Karamouzian M, Khalili M, Haji-Maghsoudi S, Salehi-Vaziri M, et al. Efficacy and Safety of a Protein-Based SARS-CoV-2 Vaccine. JAMA Network Open. 2023;6(5):e2310302. DOI: https://doi.org/10.1001/jamanetworkopen.2023.10302
18. Toledo-Romani ME, García-Carmenate M, VerdeciaSánchez L, Pérez-Rodríguez S, Rodriguez-González M, Valenzuela-Silva C, et al. Safety and immunogenicity of antiSARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults. Med (N Y). 2022;3(11):760-773.e5. DOI: https://doi.org/10.1016/j.medj.2022.08.001
19. Puga-Gómez R, Ricardo-Delgado Y, Rojas-Iriarte C, Céspedes-Henriquez L, Piedra-Bello M, Vega-Mendoza D, et al. Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children. International Journal of Infectious Diseases. 2023;126:164-173. DOI: https://doi.org/10.1016/j.ijid.2022.11.016
Supplementary files
Review
For citations:
Korsak K.S., Voropaev E.V., Osipkina O.V., Kovalev A.A., Stoma I.O. Immunological effectiveness of the booster Soberana Plus vaccine (FINLAY-FR-1A). Health and Ecology Issues. 2024;21(4):26-36. (In Russ.) https://doi.org/10.51523/2708-6011.2024-21-4-03
Views:
164
Email this article 